The interplay between eosinophils and T cells in breast cancer immunotherapy by Ioannis Zerdes, Alexios Matikas, Theodoros Foukakis

“…Treatment with immune checkpoint inhibitors (ICI) has revolutionized cancer management for multiple tumor types, including breast cancer. …”
Get full text

Liquid biopsy biomarkers to guide immunotherapy in breast cancer by Jinghan Yang, Liang Qiu, Xi Wang, Xi Chen, Pingdong Cao, Zhe Yang, Qiang Wen

“…Immune checkpoint inhibitors (ICIs) therapy has emerged as a promising treatment strategy for breast cancer (BC). …”
Get full text

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer by Chenyi Luo, Chenyi Luo, Peipei Wang, Siqi He, Jingjing Zhu, Yuanyuan Shi, Yuanyuan Shi, Jianxun Wang, Jianxun Wang

“…Although breast cancer patients in general do not have a robust response to the immunotherapy, a subset of TNBC has been demonstrated to have high tumor mutation burden and high tumor-infiltrating lymphocytes, resembling the features observed on melanoma or lung cancers, which can benefit from the treatment of immune checkpoint inhibitors (ICIs). …”
Get full text

Immunotherapy in Breast Cancer: When, How, and What Challenges? by Beatriz Henriques, Fernando Mendes, Diana Martins

“…Immune checkpoint inhibitors (ICI) showed promising efficacy in triple-negative breast cancer (TNBC) treatment, namely Atezolizumab and Pembrolizumab. …”
Get full text

Targeting PARP for the optimal immunotherapy efficiency in gynecologic malignancies by Tianye Li, Xinrun Wang, Shuang Qin, Bingxin Chen, Ming Yi, Jianwei Zhou

Get full text

Meme kanseri tanısı ile göğüs duvarına radyoterapi uygulanan hastalarda iki farklı tekniğin karşılaştırılması by Özlem Ata, Hilal Acar, Güler Yavaş, Çağdaş Yavaş

Subjects: Get full text

Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer by Luca Licata, Marco Mariani, Federico Rossari, Giulia Viale, Giulia Notini, Matteo Maria Naldini, Carlo Bosi, Marta Piras, Matteo Dugo, Giampaolo Bianchini

“…Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy and now represent the mainstay of treatment for many tumor types, including triple-negative breast cancer and two agnostic registrations. …”
Get full text

Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer by Karan Mediratta, Sara El-Sahli, Vanessa D’Costa, Lisheng Wang

“…With improved understanding of the immunogenicity of triple-negative breast cancer (TNBC), immunotherapy has emerged as a promising candidate to treat this lethal disease owing to the lack of specific targets and effective treatments. …”
Get full text

Immune Checkpoint Inhibitors in Breast Cancer: A Narrative Review by Paulo Nunes Filho, Caroline Albuquerque, Mariana Pilon Capella, Marcio Debiasi

“…Though still incurable, metastatic breast cancer’s prognosis has been considerably improved in the past 10 years due to the introduction of new targeted agents, such as immune checkpoint inhibitors (ICI). …”
Get full text

Agonist Effects of Propranolol on Non-Tumor Human Breast Cells by Lucía Gargiulo, Ezequiel Mariano Rivero, Nicolás di Siervi, Edgardo David Buzzi, Mariano Gabriel Buffone, Carlos Alberto Davio, Isabel Alicia Lüthy, Ariana Bruzzone

“…The β-blocker propranolol (PROP) has been proposed as a repurposed treatment for breast cancer. The similarity of action between β-agonists and antagonists found on breast cells encouraged us to compare PROP and isoproterenol (ISO, agonist) signaling pathways on a human breast cell line. …”
Get full text

Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges by Jin Sun Lee, Susan E. Yost, Yuan Yuan

“…Triple negative breast cancer (TNBC) is an aggressive breast cancer with historically poor outcomes, primarily due to the lack of effective targeted therapies. …”
Get full text

Progress for Immunotherapy in Inflammatory Breast Cancer and Emerging Barriers to Therapeutic Efficacy by Regina M. Koch, Daniel R. Principe, Jose L. Cataneo, Ajay Rana

“…Inflammatory breast cancer (IBC) is a rare and aggressive subtype of breast cancer that carries a particularly poor prognosis. …”
Get full text

Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome by Liying Li, Fan Zhang, Zhenyu Liu, Zhimin Fan

“…The successful application of immune checkpoint inhibitors (ICIs) launched the era of immunotherapy in TNBC. …”
Get full text

Antibody–Drug Conjugates in Breast Cancer: Current Status and Future Directions by Cynthia Mark, Jin Sun Lee, Xiaojiang Cui, Yuan Yuan

“…The rapid growth in ADC research has led to numerous developments and approvals for cancer treatment, with significant impacts on the management of breast cancer. ADCs like T-DXd for HER2-low disease and sacituzumab govitecan for triple negative breast cancer (TNBC) have provided valuable options for challenging subtypes of breast cancer. …”
Get full text

Bispecific antibodies revolutionizing breast cancer treatment: a comprehensive overview by Huan-Rong Lan, Min Chen, Shi-Ya Yao, Jun-Xia Chen, Ke-Tao Jin

“…Breast cancer (BCa) is known as a complex and prevalent disease requiring the development of novel anticancer therapeutic approaches. …”
Get full text

Immunogenomic Landscape in Breast Cancer Reveals Immunotherapeutically Relevant Gene Signatures by Tao Wang, Tianye Li, Baiqing Li, Jiahui Zhao, Zhi Li, Mingyi Sun, Yan Li, Yanjiao Zhao, Shidi Zhao, Weiguang He, Xiao Guo, Rongjing Ge, Lian Wang, Dushan Ding, Saisai Liu, Simin Min, Xiaonan Zhang, Xiaonan Zhang

“…Breast cancer is characterized by some types of heterogeneity, high aggressive behaviour, and low immunotherapeutic efficiency. …”
Get full text

Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis by Isabella Sala, Isabella Sala, Eleonora Pagan, Laura Pala, Chiara Oriecuia, Chiara Oriecuia, Marco Musca, Marco Musca, Claudia Specchia, Tommaso De Pas, Javier Cortes, Javier Cortes, Javier Cortes, Giuseppe Giaccone, Michael Postow, Richard D. Gelber, Vincenzo Bagnardi, Fabio Conforti, Fabio Conforti

Get full text

Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer by Xingyu Li, Yanyan Zhang, Cheng Zhu, Wentao Xu, Xiaolei Hu, Domingo Antonio Sánchez Martínez, José Luis Alonso Romero, Ming Yan, Ying Dai, Hua Wang

“…Abstract Background Immune checkpoint inhibitors (ICIs) can improve survivals of metastatic triple negative breast cancer (mTNBC); however, we still seek circulating blood biomarkers to predict the efficacy of ICIs. …”
Get full text

Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives by Carmine Valenza, Graziella Rizzo, Maria Ilenia Passalacqua, Laura Boldrini, Chiara Corti, Dario Trapani, Giuseppe Curigliano

“…Immune checkpoint inhibitors (ICIs) deeply changed the treatment landscape of breast cancer (BC). …”
Get full text

Genomic Features of Homologous Recombination Deficiency in Breast Cancer: Impact on Testing and Immunotherapy by Umer Ali, Sunitha Vungarala, Venkataswarup Tiriveedhi

“…Emerging evidence suggests that only a subset of breast cancer patients benefit from ICI-based immunotherapy. …”
Get full text